Ionis halves Tryngolza 2026 sales guidance to about $50 million, shares sink 19% premarket
StockTitan (Ionis release) · · AI-summarised by FinFlash
Ionis Pharmaceuticals cut its 2026 Tryngolza sales guidance to about $50 million from The Tryngolza miss raises doubts about Ionis's commercial launch execution and pressures IONS and peers in rare-disease biotech; watch whether full-year revenue guidance holds. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context